Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20325208 | 1.00 | MEN1 (0.32) | MEN1KMT2AMAPK1 | |
| SCHEMBL21471970 | 1.00 | MEN1 (0.32) | MEN1KMT2AMAPK1 | |
| SCHEMBL22965435 | 0.84 | KDM4E (0.37) | MEN1KMT2AMAPK1 | |
| SCHEMBL19935059 | 0.84 | KDM4E (0.37) | MEN1KMT2AMAPK1 | |
| SCHEMBL22566110 | 0.84 | KDM4E (0.37) | MEN1KMT2AMAPK1 | |
| SCHEMBL18611909 | 0.84 | KDM4E (0.37) | MEN1KMT2AMAPK1 | |
| SCHEMBL24789629 | 0.81 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL21899198 | 0.80 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL19606416 | 0.79 | KDM4E (0.35) | MEN1KMT2A | |
| SCHEMBL20671219 | 0.78 | KDM4E (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | MEN1 1376/4885KMT2A 754/4885MAPK1 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.